- Home
- FIBK vs DNLI Comparison
FIBK vs DNLI Comparison
Compare FIBK & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FIBK | DNLI |
|---|---|---|
| Founded | 1879 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.3B |
| IPO Year | 1997 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FIBK | DNLI |
|---|---|---|
| Price | $34.05 | $19.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $35.63 | $34.27 |
| AVG Volume (30 Days) | 1.1M | ★ 1.8M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.49% | N/A |
| EPS Growth | ★ 34.25 | N/A |
| EPS | ★ 2.94 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.89 | $444.50 |
| P/E Ratio | $11.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.93 | $12.30 |
| 52 Week High | $39.26 | $23.77 |
Technical Indicators
Market Signals| Indicator | FIBK | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 45.91 |
| Support Level | $31.37 | $18.42 |
| Resistance Level | $34.10 | $20.12 |
| Average True Range (ATR) | 0.78 | 1.21 |
| MACD | 0.24 | -0.07 |
| Stochastic Oscillator | 80.13 | 24.64 |
Price Performance
Historical ComparisonAbout FIBK First Interstate BancSystem Inc. (DE)
First Interstate BancSystem Inc is a financial holding company. It is the parent company of First Interstate Bank, a community bank offering a range of internet, mobile, and other banking and financial services throughout Idaho, Montana, Oregon, South Dakota, Washington, and Wyoming. It delivers a range of financial products and services to both retail and commercial customers in industries like agriculture, construction, education, energy, governmental services, healthcare, mining, professional services, retail, tourism and wholesale trade. It generates majority of income from interest charged on loans, and interest and dividends earned on investments.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.